

Dirección General de Mercados Edison, 4, 28006 Madrid, España (+34) 915 851 500, www.cnmv.es

LABORATORIOS FARMACEUTICOS ROVI, S.A.



2nd

HALF-YEARLY FINANCIAL REPORT FOR THE REPORTING PERIOD

2020

PERIOD END DATE

31/12/2020

I. IDENTIFICATION DETAILS

Corporate name: LABORATORIOS FARMACEUTICOS ROVI, S.A.

Registered address: c/ Julián Camarillo, 35, 28037 Madrid

Tax Id No. A-28041283

# II. INFORMATION SUPPLEMENTING THE PERIODIC INFORMATION PUBLISHED PREVIOUSLY



Dirección General de Mercados Edison, 4, 28006 Madrid, España (+34) 915 851 500, www.cnmv.es

LABORATORIOS FARMACEUTICOS ROVI, S.A.

# **IV. SELECTED FINANCIAL INFORMATION**

# 1. INDIVIDUAL STATEMENT OF FINANCIAL POSITION (PREPARED USING NATIONAL ACCOUNTING STANDARDS CURRENTLY IN FORCE)

ASSETS		CURRENT PERIOD 31/12/2020	PREVIOUS PERIOD 31/12/2019
A) NON-CURRENT ASSETS	0040	141.497	138.744
1. Intangible assets:	0030	37.487	41.587
a) Goodwill	0031		
b) Other intangible assets	0032	37.487	41.587
2. Property, plant and equipment	0033	52.130	46.742
3. Investment property	0034		
4. Non-current investments in group and associated companies	0035	45.484	42.826
5. Non-current financial investments	0036	1.484	1.482
6. Deferred tax assets	0037	4.912	6.107
7. Other non-current assets	0038		
B) CURRENT ASSETS	0085	414.030	276.732
1. Non-current assets held for sale	0050		
2. Inventories	0055	74.677	67.749
3. Trade and other receivables	0060	305.206	157.608
a) Trade receivables for sales of goods and services	0061	292.992	142.350
b) Other receivables	0062	3.872	5.169
c) Current tax assets	0063	8.342	10.089
4. Current investments in group and associated companies	0064		55
5. Current financial investments	0070		
6. Current accruals and prepayments	0071	3	3
7. Cash and cash equivalents	0072	34.144	51.317
TOTAL ASSETS (A+B)	0100	555.527	415.476



Dirección General de Mercados Edison, 4, 28006 Madrid, España (+34) 915 851 500, www.cnmv.es

LABORATORIOS FARMACEUTICOS ROVI, S.A.

# IV. SELECTED FINANCIAL INFORMATION

# 1. INDIVIDUAL FINANCIAL STATEMENTS (PREPARED USING THE NATIONAL ACCOUNTING STANDARDS CURRENTLY IN FORCE)

LIABILITIES AND EQUITY		CURRENT PERIOD 31/12/2020	PREVIOUS PERIOD 31/12/2019
A) EQUITY (A.1 + A.2 + A.3)	0195	330.686	269.329
A.1) EQUITY	0180	328.283	266.582
1. Capital:	0171	3.364	3.364
a) Authorized capital	0161	3.364	3.364
a) Less: uncalled capital	0162		
2. Share premium	0172	87.636	87.636
3. Reserves	0173	7.032	7.032
4. Less: treasury stock	0174	(20.185)	(10.341)
5. Retained earnings	0178	179.299	153.338
6. Other shareholder contributions	0179		
7. Profit or loss for period	0175	71.137	25.553
8. Less: interim dividend	0176		
9. Other equity instruments	0177		
A.2) ADJUSTMENTS FOR CHANGES IN VALUE	0188	(3)	(3)
1. Available-for-sale financial assets	0181	(3)	(3)
2. Hedging transactions	0182		
3. Other	0183		
A.3) GRANTS, DONATIONS AND LEGACIES RECEIVED	0194	2.406	2.750
B) NON-CURRENT LIABILITIES	0120	64.135	62.803
1. Non-current provisions	0115		
2. Non-current debt:	0116	53.647	54.329
a) Bank borrowings and debentures or other negotiable instruments	0131	44.825	45.000
b) Other financial liabilities	0132	8.822	9.329
3. Non-current debt with group and associated companies	0117		333
4. Deferred tax liabilities	0118	4.700	2.348
5. Other non-current liabilities	0135		
6. Non-current accruals	0119	5.788	5.793
C) CURRENT LIABILITIES	0130	160.706	83.344
1. Liabilities associated with non-current assets held for sale	0121		
2. Current provisions	0122	15.741	9.827
3. Current debt:	0123	2.867	9.138
a) Bank borrowings and debentures or other negotiable instruments	0133	175	7.116
b) Other financial liabilities	0134	2.692	2.022
4. Current debt with group and associated companies	0129	184	156
5. Trade and other payables:	0124	140.834	63.457
a) Trade payables	0125	135.148	56.674
b) Other payables	0126	5.686	6.783
c) Current tax liabilities	0127		
6. Other current liabilities	0136		
7. Current accruals	0128	1.080	766
TOTAL EQUITY AND LIABILITIES (A + B + C)	0200	555.527	415.476



Dirección General de Mercad Edison, 4, 28006 Madrid, Espa (+34) 915 851 500, www.cnmv.

LABORATORIOS FARMACEUTICOS ROVI, S.

## **IV. SELECTED FINANCIAL INFORMATION**

# 2. INDIVIDUAL INCOME STATEMENT (PREPARED USING THE NATIONAL ACCOUNTING STANDARDS CURRENTLY IN FORCE)

		CURRENT PERIOD (2nd HALF)	PREVIOUS PERIOD (2nd HALF)	ACCUMULATED PERIOD 31/12/2020	ACCUMULATED PREVIOUS PERIOD
(+) Net revenue	0205	238.953	201.812	459.424	379.221
(+/-) Change in inventories of finished products and work in progress	0206	(34.027)	1.705	(7.245)	13.653
(+) Work performed by the company on its assets	0207				
(-) Supplies	0208	(128.623)	(141.608)	(308.275)	(277.098)
(+) Other operating income	0209	3.060	1.879	5.111	3.450
(-) Employee benefit expenses	0217	(16.858)	(16.407)	(32.803)	(34.490)
(-) Other operating expenses	0210	(33.575)	(34.644)	(61.815)	(66.661)
(-) Amortization and depreciation charges	0211	(4.953)	(4.692)	(9.710)	(9.331)
(+) Allocation of grants for non-financial assets and other	0212	300	402	629	685
(+) Excess provisions	0213				
(+/-) Impairment and gains/(losses) on disposal of intangible assets and property, plant & equipment	0214	(56)	(342)	(70)	(342)
(+/-) Other gains/(losses)	0215				
= OPERATING PROFIT/(LOSS)	0245	24.221	8.105	45.246	9.087
(+) Finance income	0250	289	32	31.723	17.066
(-) Finance expenses	0251	(411)	(321)	(789)	(624)
(+/-) Change in fair value of financial instruments	0252	(1.330)	(251)	(796)	(146)
(+/-) Exchange rate differences	0254	58	(47)	77	24
(+/-) Impairment and gains/(losses) on disposal of financial instruments	0255	(511)	276	(245)	305
= FINANCE PROFIT/(LOSS)	0256	(1.905)	(311)	29.970	16.625
= PROFIT/(LOSS) BEFORE TAX	0265	22.316	7.794	75.216	25.712
(+/-) Corporate income tax	0270	(3.672)	(1.637)	(4.079)	(159)
= PROFIT/(LOSS) FOR PERIOD ON CONTINUING OPERATIONS	0280	18.644	6.157	71.137	25.553
(+/-) Profit/(loss) for perid on discontinued operations, net of tax	0285				
= PROFIT/(LOSS) FOR PERIOD	0300	18.644	6.157	71.137	25.553

EARNINGS PER SHARE		Amount (X.XX euros)	Amount (X.XX euros)	Amount (X.XX euros)	Amount (X.XX euros)
Basic	0290	0,33	0,11	1,28	0,46
Diluted	0295				



Dirección General de Mercados Edison, 4, 28006 Madrid, España (+34) 915 851 500, www.cnmv.es

LABORATORIOS FARMACEUTICOS ROVI, S.A.

# IV. SELECTED FINANCIAL INFORMATION 3. INDIVIDUAL STATEMENT OF CHANGES IN EQUITY A. INDIVIDUAL STATEMENT OF RECOGNIZED INCOME AND EXPENSES (PREPARED USING THE NATIONAL ACCOUNTING STANDARDS CURRENTLY IN FORCE)

		CURRENT PERIOD 31/12/2020	PREVIOUS PERIOD 31/12/2019
A) PROFIT/(LOSS) FOR PERIOD (from Income Statement)	0305	71.137	25.553
B) INCOME OR EXPENSES CREDITED OR CHARGED DIRECTLY TO EQUITY:	0310	514	484
1. Measurement of financial instruments	0320		
a) Available-for-sale financial assets	0021		
b) Other income /(expenses)	0323		
2. Cash flow hedges	0330		
3. Grants, donations and legacies received	0340	686	646
4. Actuarial gains and losses and other adjustments	0344		
5. Other income or expenses credited or charged directly to equity	0343		
6. Tax effect	0345	(172)	(162)
C) TRANSFERS TO PROFIT AND LOSS:	0350	(858)	(862)
1. Measurement of financial instruments	0355		
a) Available-for-sale financial assets	0356		
b) Other income /(expenses)	0358		
2. Cash flow hedges	0360		
3. Grants, donations and legacies received	0366	(1.145)	(1.151)
4. Other income or expenses credited or charged directly to equity	0365		
5. Tax effect	0370	287	289
TOTAL RECOGNIZED INCOME/(EXPENSES) (A+B+C)	0400	70.793	25.175



Dirección General de Mercados Edison, 4, 28006 Madrid, España (+34) 915 851 500, www.cnmv.es

LABORATORIOS FARMACEUTICOS ROVI, S.A.

# IV. SELECTED FINANCIAL INFORMATION

# 3. INDIVIDUAL STATEMENT OF CHANGES IN EQUITY B. INDIVIDUAL STATEMENT OF CHANGES IN TOTAL EQUITY (1/2) (PREPARED USING THE NATIONAL ACCOUNTING STANDARDS CURRENTLY IN FORCE)

				Equity					
CURRENT PERIOD		Share capital	Share premium and reserves	Treasury stock	Profit/ (loss) for the period	Other equity instru- ments	Adjust- ments for changes in value	Grants, donations and legacies received	Total equity
Closing balance at 01/01/2020	3010	3.364	248.006	(10.341)	25.553		(3)	2.750	269.329
Adjustments for changes in accounting policies	3011								
Adjustments for errors	3012								
Adjusted opening balance	3015	3.364	248.006	(10.341)	25.553		(3)	2.750	269.329
I. Total recognized income/(expenses)	3020				71.137			(344)	70.793
II. Transactions with shareholders or owners	3025		10.077	(9.844)	(9.700)				(9.467)
1. Capital increases/(reductions)	3026								
2. Conversion of financial liabilities to equity	3027								
<ol> <li>Distribution of dividends</li> </ol>	3028				(9.700)				(9.700)
4. Treasury stock transactions (net)	3029		10.077	(9.844)					233
5.Increases/(reductions ) due to business combinations	3030								
<ol> <li>Other transactions with shareholders or owners</li> </ol>	3032								
III. Other equity transactions	3035		15.884		(15.853)				31
1. Payments based on equity instruments	3036								
2. Transfers between equity items	3037		15.853		(15.853)				
3. Other changes	3038		31						31
Closing balance at 31/12/2020	3040	3.364	273.967	(20.185)	71.137		(3)	2.406	330.686



Dirección General de Mercados Edison, 4, 28006 Madrid, España (+34) 915 851 500, www.cnmv.es

LABORATORIOS FARMACEUTICOS ROVI, S.A.

# IV. SELECTED FINANCIAL INFORMATION

# 3. INDIVIDUAL STATEMENT OF CHANGES IN EQUITY B. INDIVIDUAL STATEMENT OF CHANGES IN TOTAL EQUITY (2/2) (PREPARED USING THE NATIONAL ACCOUNTING STANDARDS CURRENTLY IN FORCE)

				Equity					
PREVIOUS PERIOD		Share capital	Share premium and reserves	Treasury stock	Profit/ (loss) for the period	Other equity instrume nts	Adjustment s for changes in value	Grants, donations and legacies received	Total equity
Closing balance at 01/01/2019 (comparative period)	3050	3.364	235.163	(8.812)	15.581		(3)	3.128	248.421
Adjustments for changes in accounting policies	3051								
Adjustments for errors	3052								
Adjusted opening balance (comparative period)	3055	3.364	235.163	(8.812)	15.581		(3)	3.128	248.421
I. Total recognized income/(expenses)	3060				25.553			(378)	25.175
II. Transactions with shareholders or owners	3065		1.682	(1.529)	(4.420)				(4.267)
1. Capital increases/(reductions)	3066								
2. Conversion of financial liabilities to equity	3067								
3. Distribution of dividends	3068				(4.420)				(4.420)
4. Treasury stock transactions (net)	3069		1.682	(1.529)					153
5.Increases/ (reductions) due to business combinations	3070								
<ol> <li>Other transactions with shareholders or owners</li> </ol>	3072								
III. Other equity	3075		11.161		(11.161)				
transactions	0010				(11.101)				
1. Payments based on equity instruments	3076								
2. Transfers between equity items	3077		11.161		(11.161)				
3. Other changes	3078								
Closing balance at 31/12/2019 (comparative period)	3080	3.364	248.006	(10.341)	25.553		(3)	2.750	269.329



Dirección General de Mercados Edison, 4, 28006 Madrid, España (+34) 915 851 500, www.cnmv.es

LABORATORIOS FARMACEUTICOS ROVI, S.A.

## **IV. SELECTED FINANCIAL INFORMATION**

# 4. INDIVIDUAL STATEMENT OF CASH FLOWS (PREPARED USING NATIONAL ACCOUNTING STANDARDS CURRENTLY IN FORCE)

Units: thousands of euros			
		CURRENT PERIOD 31/12/2020	PREVIOUS PERIOD 31/12/2019
A) CASH FLOWS FROM OPERATING ACTIVITIES (1+2+3+4)	0435	13.905	(30.035)
1.Profit/(loss) before tax	0405	75.216	25.712
2. Adjustments to profit/(loss)	0410	12.953	12.152
(+) Amortization and depreciation of intangible assets and property, plant and equipment	0411	9.710	9.331
(+/-) Other adjustments to profit/(loss) (net)	0412	3.243	2.821
3. Changes in working capital	0415	(69.633)	(60.206)
4. Other cash flows from operating activities:	0420	(4.631)	(7.693)
(-) Payment of interest	0421		
(+) Proceeds from dividends	0422		
(+) Proceeds from interest	0423		
(+/-) Proceeds from/(payments for) corporate income tax	0430	(5.884)	(8.087)
(+/-) Other proceeds from/(payments for) operating activities	0425	1.253	394
B) CASH FLOWS FROM INVESTING ACTIVITIES (1+2)	0460	(10.261)	(26.382)
1. Payments of investments:	0440	(11.074)	(26.539)
(-) Group companies, associates and business units	0441		(775)
(-) Property, plant and equipment, intangible assets and investment property	0442	(11.074)	(25.764)
(-) Other financial assets	0443		
(-) Non-current assets and liabilities classified as held for sale	0459		
(-) Other assets	0444		
2. Proceeds from disinvestments	0450	813	157
(+) Group companies, associates and business units	0451	144	
(+) Property, plant and equipment, intangible assets and investment property	0452	20	75
(+) Other financial assets	0453		
(+) Non-current assets and liabilities classified as held for sale	0461		
(+) Other assets	0454	649	82
C) CASH FLOWS FROM FINANCING ACTIVITIES (1+2+3)	0490	(20.817)	23.947
1. Proceeds from and (payments for) equity instruments:	0470	233	153
(+) Issue	0471		
(-) Amortization	0472		
(-) Acquisition	0473	(37.255)	(4.718)
(+) Disposal	0474	37.488	4.871
(+) Grants, donations and legacies received	0475		
2. Proceeds from and (payments for) financial liability instruments:	0480	(11.350)	28.214
(+) Issue	0481	1.430	47.033
(-) Repayment and amortization	0482	(12.780)	(18.819)
3. Payment of dividends and remuneration of other equity instruments	0485	(9.700)	(4.420)
D) EFFECT OF EXCHANGE RATE CHANGES	0492		
E) NET INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS (A+B+C+	0495	(17.173)	(32.470)
F) CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	0499	51.317	83.787
G) CASH AND CASH EQUIVALENTS AT END OF PERIOD (E+F)	0500	34.144	51.317

COMPONENTS OF CASH AND CASH EQUIVALENTS AT END OF PERIOD		CURRENT PERIOD 31/12/2020	PREVIOUS PERIOD 31/12/2019
(+) Cash in hand and at bank	0550	34.144	51.317
(+) Other financial assets	0552		
(-) Less: bank overdrafts repayable on demand	0553		
TOTAL CASH AND CASH EQUIVALENTS AT END OF PERIOD	0600	34.144	51.317



Dirección General de Mercados Edison, 4, 28006 Madrid, España (+34) 915 851 500, www.cnmv.es

LABORATORIOS FARMACEUTICOS ROVI, S.A.

## **IV. SELECTED FINANCIAL INFORMATION**

## 5. CONSOLIDATED STATEMENT OF FINANCIAL POSITION (UNDER IFRS ADOPTED) (1/2)

ASSETS		CURRENT PERIOD 31/12/2020	PREVIOUS PERIOD 31/12/2019
A) NON-CURRENT ASSETS	1040	209.861	193.326
1. Intangible assets:	1030	41.413	45.079
a) Goodwill	1031		
b) Other intangible assets	1032	41.413	45.079
2. Property, plant and equipment	1033	155.395	131.608
3. Investment property	1034		
4. Investments in group and associated companies accounted for using the equity me	1035	1.812	1.843
5. Non-current financial investments	1036	71	71
a) At fair value through profit or loss	1047	71	71
Of which, "Designated upon initial recognition"	1041		
b) At fair value through other comprehensive income	1042		
Of which, "Designated upon initial recognition"	1043		
c) At amortised cost	1044		
6. Non-current derivatives	1039		
a) Hedging instruments	1045		
b) Other	1046		
7. Deferred tax assets	1037	11.105	14.660
8. Other non-current assets	1038	65	65
B) CURRENT ASSETS	1085	364.578	317.885
1. Non-current assets held for sale	1050		
2. Inventories	1055	227.199	158.811
3. Trade and other receivables	1060	84.204	91.645
a) Trade receivables for sale of goods and services	1061	63.285	71.616
b) Other receivables	1062	13.116	9.925
c) Current tax assets	1063	7.803	10.104
4. Current financial assets	1070		
a) At fair value through profit or loss	1080		
Of which, "Designated upon initial recognition"	1081		
b) At fair value through other comprehensive income	1082		
Of which, "Designated upon initial recognition"	1083		
c) At amortised cost	1084		
5.Current derivatives	1076		
a) Hedging instruments	1077		
b) Other	1078		
6. Other current assets	1075	13	3
7. Cash and cash equivalents	1072	53.162	67.426
TOTAL ASSETS (A+B)	1100	574.439	511.211



Dirección General de Mercados Edison, 4, 28006 Madrid, España (+34) 915 851 500, www.cnmv.es

LABORATORIOS FARMACEUTICOS ROVI, S.A.

## **IV. SELECTED FINANCIAL INFORMATION**

# 5. CONSOLIDATED STATEMENT OF FINANCIAL POSITION (UNDER IFRS ADOPTED) (2/2)

Units: thousands of euros LIABILITIES AND EQUITY	CURRENT PERIOD 31/12/2020	PREVIOUS PERIOD 31/12/2019	
A) EQUITY (A.1 + A.2 + A.3)	1195	373.700	322.386
A.1) EQUITY	1180	373.703	322.389
1. Capital:	1171	3.364	3.364
a) Authorized capital	1161	3.364	3.364
b) Less: uncalled capital	1162	0.001	0.001
2. Share premium	1172	87.636	87.636
3. Reserves	1173	673	673
4. Less treasury stock	1174	(20.185)	(10.341)
5. Retained earnings	1178	241.158	201.784
6. Other shareholder contributions	1179	2111100	2011/01
7. Profit or loss for period	1175	61.057	39.273
8. Less: interim dividend	1175	01.007	00.270
	1170		
9. Other equity instruments	1177	(2)	(2)
A.2) ACCUMULATED OTHER COMPREHENSIVE INCOME		(3)	(3)
1. Items not reclassified to profit and loss for the period	1186		
a) Equity instruments held at fair value through other comprehensive income	1185		
b) Other	1190	(0)	(0)
2. Items that may be reclassified to profit and loss for the period	1187	(3)	(3)
a) Hedging transactions	1182		
b) Hedging differences	1184		
c) Share in other comprehensive income of joint ventures and other	1192		
d) Debt instruments held at fair value through other comprehensive income	1191		
e) Other	1183	(3)	(3)
EQUITY ATTRIBUTED TO PARENT COMPANY (A.1 + A.2)	1189	373.700	322.386
A.3) NON-CONTROLLING INTERESTS	1193		
B) NON-CURRENT ASSETS	1120	77.850	82.116
1. Grants	1117		
2. Non-current provisions	1115		
3. Non-current financial liabilities:	1116	68.421	72.104
a) Bank borrowings and debentures or other negotiable securities	1131	44.825	45.000
b) Other financial liabilities	1132	23.596	27.104
4. Deferred tax liabilities	1118	929	1.078
5. Non-current derivatives	1140		
a) Hedging instruments	1141		
b) Other	1142		
6. Other non-current liabilities	1135	8.500	8.934
C) CURRENT LIABILITIES	1130	122.889	106.709
1. Liabilities related to current assets held for sale	1121		
2. Current provisions	1122		
3. Current finanacial liabilities:	1123	5.097	12.572
a) Bank borrowings and debentures or other negotiable securities	1133	175	7.116
b) Other financial liabilities	1134	4.922	5.456
4. Trade and other payables:	1124	91.364	91.914
a) Trade payables	1125	63.452	68.770
b) Other payables	1126	27.912	23.144
c) Current tax liabilities	1127		
5. Current derivatives	1127	925	129
a) Hedging instruments	1145	925	129
b) Other	1140	525	123
,	1147	25.503	2.094
5. Other current liabilities			



Dirección General de Mercados Edison, 4, 28006 Madrid, España (+34) 915 851 500, www.cnmv.es

LABORATORIOS FARMACEUTICOS ROVI, S.A.

# IV. SELECTED FINANCIAL INFORMATION 6. CONSOLIDATED INCOME STATEMENT (UNDER IFRS ADOPTED)

Units: thousands of euros		CURRENT	PREVIOUS	ACCUMULA	ACCUMULAT
		PERIOD (2nd HALF)	PERIOD (2nd HALF)	TED PERIOD 31/12/2020	PREVIOUS PERIOD 31/12/2019
(+) Net revenue	1205	228.832	203.777	419.961	381.313
(+/-) Change in inventories of finished products and work in	1006	(10,176)	524	17 650	21.414
progress	1206	(19.176)	534	17.659	21.414
(+) Work performed by the company on its assets	1207				
(-) Supplies	1208	(80.073)	(91.082)	(196.311)	(188.020)
(+) Other operating income	1209				
(-) Employee benefit expenses	1217	(37.877)	(35.759)	(74.429)	(72.512)
(-) Other operating expenses	1210	(40.363)	(43.314)	(73.706)	(81.946)
(-) Amortization and depreciation charges	1211	(10.052)	(9.501)	(19.593)	(18.216)
(+) Allocation of grants for non-financial assets and other	1212	556	777	1.157	1.151
(+/-) Impairment of intangible assets and property, plant &		(50)	(2.14)		
equipment	1214	(56)	(341)	(56)	(341)
(+/-) Gains/(losses) on disposal of intangible assets and					
property, plant & equipment	1216				
(+/-) Other gains/(losses)	1215				
= OPERATING PROFIT/(LOSS)	1245	41.791	25.091	74.682	42.843
(+) Finance income	1250	2	48	4	51
a) Interest income calculated using the effective interest rate					
method	1262	2	48	4	51
b) Other	1263				
(-) Finance expenses	1251	(221)	(475)	(1.072)	(927)
(+/-) Change in fair value of financial instruments	1252	(1.330)	(251)	(796)	(146)
(+/-) Gains/(losses) due to the reclassification of financial		(1.000)	(201)	(100)	(110)
assets held at amortised cost to financial assets held at fair	1258				
value					
(+/-) Gains/(losses) due to the reclasification of financial					
assets held at fair value through other comprehensive income	1259				
to financial assets held at fair value	1200				
(+/-) Exchange rate differences	1254	18	(88)	39	(51)
(+/-) Impairment on disposal of financial instruments	1255	10	(00)		(31)
(+/-) Gains/(losses) on disposal of financial instruments	1255	(511)	276	(245)	305
a) Financial instruments at amortised cost	1257	(311)	270	(243)	303
b) Rest of financial instruments	1260	(511)	276	(245)	305
= FINANCE PROFIT/(LOSS)	1256	(2.042)	(490)	(243)	(768)
	1253	· · · · · · · · · · · · · · · · · · ·	(185)		(195)
(+/-) Profit/(loss) of entities measured using the equity method = PROFIT/(LOSS) BEFORE TAX	1255	(9) 39.740	24.416	(31) 72.581	41.880
	1205				
(+/-) Corporate income tax = PROFIT/(LOSS) FOR PERIOD FROM CONTINUING	12/0	(8.276)	(1.304)	(11.524)	(2.607)
OPERATIONS	1280	31.464	23.112	61.057	39.273
(+/-)Profit/(loss) for period from discontinued operations, net	1285				
	4000		00.410	04.07-	00.070
= CONSOLIDATED PROFIT/(LOSS) FOR PERIOD	1288	31.464	23.112	61.057	39.273
a) Profit/(loss) attributed to parent company	1300	31.464	23.112	61.057	39.273
b) Profit/(loss) attributed to non-controlling interests	1289				

EARNINGS PER SHARE		AMOUNT (X.XX euros)	AMOUNT (X.XX euros)	AMOUNT (X.XX euros)	AMOUNT (X.XX euros)
Basic	1290	0,57	0,42	1,10	0,71
Diluted	1295				



Dirección General de Mercados Edison, 4, 28006 Madrid, España (+34) 915 851 500, www.cnmv.es

LABORATORIOS FARMACEUTICOS ROVI, S.A.

### **IV. SELECTED FINANCIAL INFORMATION**

## 7. CONSOLIDATED STATEMENT OF RECOGNIZED INCOME AND EXPENSES (UNDER IFRS ADOPTED)

Units: thousands of euros		CURRENT PERIOD (2nd HALF)	,	CURRENT PERIOD 31/12/2020	PREVIOUS PERIOD 31/12/2019
A) PROFIT/(LOSS) FOR PERIOD (from Income Statement)	1305	31.464	23.112	61.057	39.273
B) OTHER COMPREHENSIVE INCOME - ITEMS NOT					
RECLASSIFIED TO PROFIT AND LOSS FOR THE PERIOD	1310				
1. Remeasurement (reversal of remeasurement) of property, plant					
and equipment and intangible assets	1311				
2. Actuarial gains and losses	1344				
3. Share in other recognized comprehensive income from					
investments in joint ventures and associates	1342 1346				
4. Equity instruments held at fair value through other	1346				
5. Other income and expenses not reclassified to profit and loss for	1343				
the period 6. Tax effect	1345				
	1345				
C) OTHER COMPREHENSIVE INCOME - ITEMS THAT MAY SUBSEQUENTLY BE RECLASSFIED TO PROFIT AND LOSS FOR	1350				
1. Hedging transactions:	1360				
a) Gains/(losses) on remeasurement	1361				
b) Amounts transferred to profit and loss	1362				
c) Amounts transferred at initial value of hedged items	1363				
d) Other reclassifications	1364				
2. Conversion differences:	1365				
a) Gains/(losses) on remeasurement	1366				
b) Amounts transferred to profit and loss	1367				
c) Other reclassifications	1368				
3. Share in other recognized comprehensive income from	1370				
investments in joint ventures and associates	1370				
a) Gains/(losses) from measurement	1371				
b) Amounts transferred to profit and loss	1372				
c) Other reclassifications	1373				
4. Debt instruments held at fair value through other comprehensive income:	1381				
a) Gains/(losses) on remeasurement	1382				
b) Amounts transferred to profit and loss	1383				
c) Other reclassifications	1384				
5. Other comprehensive income and expenses that may subsequently be reclassified to profit and loss for the period:	1375				
a) Gains/(losses) on remeasurement	1376				
b) Amounts transferred to profit and loss	1370				
c) Other reclassifications	1978				
· · · ·					
6. Tax effect	1380	21.404	22.440	61.057	20.070
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD (A+B+C)	1400	31.464	23.112	61.057	39.273
a) Attributed to parent company	1398	31.464	23.112	61.057	39.273
b) Attributed to non-controlling interests	1399				



Dirección General de Mercados Edison, 4, 28006 Madrid, España (+34) 915 851 500, www.cnmv.es

LABORATORIOS FARMACEUTICOS ROVI, S.A.

# IV. SELECTED FINANCIAL INFORMATION

# 8. CONSOLIDATED STATEMENT OF CHANGES IN TOTAL EQUITY (UNDER IFRS ADOPTED) (1/2)

			Equit	y attributed	to parent c	ompany			
				Equity					
CURRENT PERIOD		Share capital	Share premium and reserves	Treasury stock	Profit/ (loss) for the per. attributed to parent company	Other equity instru- ments	Adjust- ments for changes in value	Non- controlling interests	Total equity
Closing balance at 01/01/2020	3110	3.364	290.093	(10.341)	39.273		(3)		322.386
Adjustments for changes in accounting policies	3111								
Adjustments for errors	3112								
Adjusted opening balance	3115	3.364	290.093	(10.341)	39.273		(3)		322.386
I. Total recognized	3120				61.057				61.057
income/(expenses)									
II. Transactions with shareholders or owners	3125		10.077	(9.844)	(9.700)				(9.467)
1. Capital increases/(reductions)	3126								
2. Conversion of financial liabilities to equity	3127								
3. Distribution of dividends	3128				(9.700)				(9.700)
4. Treasury stock transactions (net)	3129		10.077	(9.844)					233
5.Increases/(reductions) due to business combinations	3130								
6. Other transactions with shareholders or owners	3132								
III. Other equity transactions	3135		29.297		(29.573)				(276)
1. Payments based on equity instruments	3136								
2. Transfers between equity items	3137		29.573		(29.573)				
3. Other changes	3138		(276)						(276)
Closing balance at 31/12/2020	3140	3.364	329.467	(20.185)	61.057		(3)		373.700



Dirección General de Mercados Edison, 4, 28006 Madrid, España (+34) 915 851 500, www.cnmv.es

LABORATORIOS FARMACEUTICOS ROVI, S.A.

# **IV. SELECTED FINANCIAL INFORMATION**

# 8. CONSOLIDATED STATEMENT OF CHANGES IN TOTAL EQUITY (UNDER IFRS ADOPTED) (2/2)

			Equit	y attributed	to parent c	ompany			
				Equity					
PREVIOUS PERIOD		Share capital	Share premium and reserves	Treasury stock	Profit/ (loss) for the per. attributed to parent company	Other equity instru- ments	Adjust- ments for changes in value	Non- controlling interests	Total equity
Closing balance at									
01/01/2019 (comparative	3150	3.364	275.028	(8.812)	17.895		(3)		287.472
period)									
Adjustments for changes in	3151								
accounting policies	3151								
Adjustments for errors	3152								
Adjusted opening balance	3155	3.364	275.028	(8.812)	17.895		(3)		287.472
I. Total recognized	3160				39.273				39.273
income/(expenses)	3100				39.273				39.273
II. Transactions with	3165		1.682	(1.529)	(4.420)				(4.267)
shareholders or owners	3105		1.002	(1.529)	(4.420)				(4.207)
1. Capital	3166								
increases/(reductions)	5100								
2. Conversion of financial	3167								
liabilities to equity									
3. Distribution of dividends	3168				(4.420)				(4.420)
<ol> <li>Treasury stock transactions (net)</li> </ol>	3169		1.682	(1.529)					153
5.Increases/(reductions) due to business combinations	3170								
6. Other transactions with									
shareholders or owners	3172								
III. Other equity	3175		13.383		(13.475)				(92)
transactions					· ,				· , ,
1. Payments based on equity	3176								
instruments									
2. Transfers between equity	3177		13.475		(13.475)				
items 3. Other changes	3178		(92)		, I				(92)
	3176		(92)						(92)
Closing balance at 31/12/2019 (comparative	3180	3.364	290.093	(10.341)	39.273		(3)		322.386
	3100	3.304	290.093	(10.341)	39.273		(3)		322.300
period)									



(+) Other financial assets

(-) Less: bank overdrafts repayable on demand

TOTAL CASH AND CASH EQUIVALENTS AT END OF PERIOD

Dirección General de Mercados Edison, 4, 28006 Madrid, España (+34) 915 851 500, www.cnmv.es

LABORATORIOS FARMACEUTICOS ROVI, S.A.

### **IV. SELECTED FINANCIAL INFORMATION**

## 9.A. CONSOLIDATED STATEMENT OF CASH FLOWS (INDIRECT METHOD) (UNDER IFRS ADOPTED)

Units: thousands of euros		CURRENT PERIOD 31/12/2020	PREVIOUS PERIOD 31/12/2019
A) CASH FLOWS FROM OPERATING ACTIVITIES (1 + 2 + 3 + 4)	1435	46.876	(9.044)
1.Profit/(loss) before tax	1405	72.581	41.880
2. Adjustments to profit/(loss)	1410	21.365	17.769
(+) Amortization and depreciation of intangible assets and property, plant and equipment	1411	19.593	18.216
(+/-) Other adjustments to profit/(loss) (net)	1412	1.772	(447)
3. Changes in working capital	1415	(63.751)	(63.665)
4. Other cash flows from operating activities:	1420	16.681	(5.028)
(-) Payment of interest	1421		
(-) Payment of dividends and remuneration of other equity instruments	1430		
(+) Proceeds from dividends	1422		
(+) Proceeds from interest	1423	(151)	(93)
(+/-) Proceeds from/(payments of) corporate income tax	1424	(6.038)	(8.129)
(+/-) Other proceeds from/(payments for) operating activities	1425	22.870	3.194
B) CASH FLOWS FROM INVESTING ACTIVITIES (1+2+3)	1460	(39.625)	(40.472)
1. Payments of investments:	1440	(39.692)	(40.525)
(-) Group companies, associates and business units	1441	,	· · · · ·
(-) Property, plant and equipment, intangible assets and investment property	1442	(39.692)	(40.525)
(-) Other financial assets	1443	(/	( /
(-) Non-current assets and liabilities classified as held for sale	1459		
(-) Other assets	1444		
2. Proceeds from disinvestments	1450	63	2
(+) Group companies, associates and business units	1451		
(+) Property, plant and equipment, intangible assets and investment property	1452	63	2
(+) Other financial assets	1453	00	L
(+) Non-current assets and liabilities classified as held for sale	1461		
(+) Other assets	1454		
3. Other cash flows from investing activities	1455	4	51
(+) Proceeds from dividends	1456	т Т	01
(+) Proceeds from interest	1457	4	51
(+/-) Other proceeds from/(payments for) investing activities	1458	т Т	01
C) CASH FLOWS FROM FINANCING ACTIVITIES (1+2+3+4)	1490	(21.515)	21.431
1. Proceeds from and (payments of) equity instruments:	1430	233	153
(+) Issue	1471	200	100
(-) Amortization	1472		
(-) Acquisition	1472	(37.255)	(4.718)
(+) Disposal		37.488	4.871
2. Proceeds from/ (payments for) financial liability instruments:	1474 1480	(11.749)	25.791
(+) Issue	1480	1.430	47.033
(-) Repayment and amortization	1481	(13.179)	(21.242)
		(9.700)	(4.420)
3. Payment of dividends and remuneration of other equity instruments 4. Other cash flows from financing activities	1485 1486	(9.700)	(4.420)
(-) Payment of interest	1480	(299)	(93)
(+/-) Other proceeds from /(payments for) financing activities	1487	(299)	(93)
D) EFFECT OF CHANGES IN EXCHANGE RATES	1466		
E) NET INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS (A+B+C+D)	1492	(14.264)	(28.085)
E) NET INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS (A+B+C+D) F) CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	1495	(14.264) 67.426	(28.085) 95.511
G) CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD G) CASH AND CASH EQUIVALENTS AT END OF PERIOD (E+F)		53.162	
UJ CAON AND CAON EQUIVALENTO AT END OF PERIOD (E+F)	1500	33.102	67.426
COMPONENTS OF CASH AND CASH EQUIVALENTS AT END OF PERIOD		CURRENT PERIOD 31/12/2020	PREVIOUS PERIOD 31/12/2019
(+) Cash in hand and at bank	1550	53.162	67.426
	1550		-

1552

1553

1600

53.162

67.426



Dirección General de Mercados Edison, 4, 28006 Madrid, España (+34) 915 851 500, www.cnmv.es

LABORATORIOS FARMACEUTICOS ROVI, S.A.

# IV. SELECTED FINANCIAL INFORMATION 10. DIVIDENDS PAID

				PREVIOU	S PERIOD
		Euros per share (X.XX)	Amount (thousand euros)	Euros per share (X.XX)	Amount (thousand euros)
Ordinary shares	2158	0,18	9.818	0,08	4.474
Other shares (non-voting, redeemable, etc.)	2159				
Total dividends paid	2160	0,18	9.818	0,08	4.474
a) Dividends charged to profit and loss	2155	0,18	9.818	0,08	4.474
a) Dividends charged to reserves or share premium	2156				
c) Dividends in kind	2157				
d) Flexible payment	2154				



Dirección General de Mercados Edison, 4, 28006 Madrid, España (+34) 915 851 500, www.cnmv.es

LABORATORIOS FARMACEUTICOS ROVI, S.A.

# IV. SELECTED FINANCIAL INFORMATION 11. SEGMENT REPORTING

# Units: thousands of euros

Table 1:

		Distribution of net revenue by geographical area						
GEOGRAPHICAL AREA		INDIV	IDUAL	CONSO	LIDATED			
		CURRENT PERIOD	PREVIOUS PERIOD	CURRENT PERIOD PREVIOUS PERI				
Domestic market	2210	353.864	284.475	228.821	232.266			
Exports:	2215	105.560	94.746	191.140	149.047			
a) European Union	2216	76.571	77.691	127.211	129.825			
Eurozone	2217	76.621	71.521	127.261	105.217			
Non Eurozone	2218	(50)	6.170	(50)	24.608			
c) Other countries	2219	28.989	17.055	63.929	19.222			
TOTAL	2220	459.424	379.221	419.961	381.313			

Table 2:

			CONSOLIDATED						
			ue from external omers	Profit or loss					
SEGMENTS		CURRENT PERIOD	PREVIOUS PERIOD	<b>CURRENT PERIOD</b>	PREVIOUS PERIOD				
Manufacturing	2221	239.683	197.512	24.602	30.221				
Marketing	2222	463.737	392.727	71.138	28.153				
Other	2223			(28)	(33)				
	2224								
	2225								
	2226								
	2227								
	2228								
	2229								
(-)Adjustments between segments	2230	(283.459)	(208.926)	(34.655)	(19.068)				
TOTAL	2235	419.961	381.313	61.057	39.273				



Dirección General de Mercados Edison, 4, 28006 Madrid, España (+34) 915 851 500, www.cnmv.es

LABORATORIOS FARMACEUTICOS ROVI, S.A.

# IV. SELECTED FINANCIAL INFORMATION 12. AVERAGE NUMBER OF EMPLOYEES

		INDIV	IDUAL	CONSO	LIDATED
		CURRENT	PREVIOUS	CURRENT	PREVIOUS
		PERIOD	PERIOD	PERIOD	PERIOD
AVERAGE NUMBER OF EMPLOYEES	2295	516	506	1.364	1.293
Men	2296	223	216	639	600
Women	2297	293	290	725	693

# IV. SELECTED FINANCIAL INFORMATION 13. COMPENSATION RECEIVED BY DIRECTORS AND SENIOR MANAGEMENT

### DIRECTORS:

Item of compensation:	CURRENT PERIOD	PREVIOUS PERIOD			
Remuneration for membership of Board or Board committees	2310	585	510		
Salaries	2311	811	787		
Variable cash remuneration	2312	403	383		
Share-based remuneration systems	2313				
Indemnities	2314				
Long-term savings systems	2315	24	24		
Other	2316				
TOTAL	2320	1.823	1.704		

	Amount (tho	usand euros)	
SENIOR MANAGEMENT:	CURRENT	PREVIOUS	
		PERIOD	PERIOD
Total compensation received by senior management	2325	1.688	1.894



Dirección General de Mercados Edison, 4, 28006 Madrid, España (+34) 915 851 500, www.cnmv.es

LABORATORIOS FARMACEUTICOS ROVI, S.A.

# IV. SELECTED FINANCIAL INFORMATION 14. RELATED-PARTY TRANSACTIONS AND BALANCES (1/2)

		CURRENT PERIOD				
EXPENSES AND INCOME		Significant share- holders	Directors and senior manage- ment	Persons, companies or entities belonging to the group	Other related parties	Total
1) Finance expenses	2340					
2) Rentals	2343		25		2.033	2.058
3) Services received	2344					
4) Purchases of goods (finished or in progress)	2345					
5) Other expenses	2348					
EXPENSES (1+2+3+4+5)	2350		25		2.033	2.058
6) Finance income	2351				22	22
7) Dividends received	2354					
8) Services provided	2356					
9) Sale of goods (finished or in progress)	2357					
10) Other income	2359					
INCOME (6+7+8+9+10)	2360				22	22

		CURRENT PERIOD				
OTHER TRANSACTIONS		Significant share- holders	Directors and senior manage- ment	Persons, companies or entities belonging to the group	Other related parties	Total
Financing agreements: loans & capital contributions (lender)	2372					
Financing agreements: loans & capital contributions (borrower)	2375					
Guarantees and guarantee deposits furnished	2381					
Guarantees and guarantee deposits received	2382					
Commitments acquired	2382					
Dividends and other profits distributed	2386	6.743				6.743
Other transactions	2385					

		CURRENT PERIOD				
BALANCES AT END OF PERIOD		Significant share- holders	Directors and senior manage- ment	Persons, companies or entities belonging to the group	Other related parties	Total
1) Customers and trade debtors	2341					
2) Loans and credits granted	2342					
3) Other amounts receivable	2346					
TOTAL BALANCES RECEIVABLE (1+2+3)	2347					
<ol><li>Suppliers and trade creditors</li></ol>	2352					
5) Loans and credits received	2353					
6) Other payment obligations	2355					
OTHER BALANCES PAYABLE (4+5+6)	2358					



Dirección General de Mercados Edison, 4, 28006 Madrid, España (+34) 915 851 500, www.cnmv.es

LABORATORIOS FARMACEUTICOS ROVI, S.A.

# IV. SELECTED FINANCIAL INFORMATION 14. RELATED-PARTY TRANSACTIONS AND BALANCES (2/2)

RELATED-PARTY TRANSACTIONS		PREVIOUS PERIOD						
EXPENSES AND INCOME		Significant share- holders	Directors and senior manage- ment	Persons, companies or entities belonging to the group	Other related parties	Total		
1) Finance expenses	6340							
2) Rentals	6343		25		2.036	2.061		
3) Services received	6344							
4) Purchases of goods (finished or in progress)	6345							
5) Other expenses	6348							
EXPENSES (1+2+3+4+5)	6350		25		2.036	2.061		
6) Finance income	6351							
7) Dividends received	6354							
8) Services provided	6356							
9) Sale of goods (finished or in progress)	6357							
10) Other income	6359							
INCOME (6+7+8+9+10)	6360							

		PREVIOUS PERIOD				
OTHER TRANSACTIONS		Significant share- holders	Directors and senior manage- ment	Persons, companies or entities belonging to the group	Other related parties	Total
Financing agreements: loans & capital contributions (lender)	6372					
Financing agreements: loans & capital contributions (borrower)	6375					
Guarantees and guarantee deposits furnished	6381					
Guarantees and guarantee deposits received	6382					
Commitments acquired	6382					
Dividends and other profits distributed	6386					
Other transactions	6385					

		PREVIOUS PERIOD				
BALANCES AT END OF PERIOD		Significant share- holders	Directors and senior manage- ment	Persons, companies or entities belonging to the group	Other related parties	Total
1) Customers and trade debtors	6341					
<ol><li>Loans and credits granted</li></ol>	6342					
3) Other amounts receivable	6346					
TOTAL BALANCES RECEIVABLE (1+2+3)	6347					
<ol><li>Suppliers and trade creditors</li></ol>	6352					
5) Loans and credits received	6353					
<ol><li>Other payment obligations</li></ol>	6355					
OTHER BALANCES PAYABLE (4+5+6)	6358					